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The authors report on the variability in the integrated quantity of free (unbound) plasma cisplatin (area under curve 
of plasma concentration versus time, AUC). The AUC was measured in 19 patients receiving cisplatin doses 
proportional to body surface areas (BSA), 30mg/m2 over 1 hour. The relative standard deviation (RSD, population 
standard deviation divided by mean value) for the maximum free plasma cisplatin concentration (Cmax, μM) was 
0.338; for the half-life (t½, minute), 0.210; and for the AUC (μM minute), 0.320. Thus, BSA-based dosing gave 
significant variability in the AUC. We attempted to use (weight)a(height)b, seeking values of a and b that gave the 
smallest RSD in AUC, but only minimal improvement could be obtained by deviating from the BSA formula (a = b 
= 0.5). However, dosing proportional to (weight)d(Cmax)f (with d ≈ 3/4 and f ≈ –1) reduced the RSD in AUC from 
~1/3 to ~1/10. Dosing proportional to (weight)m(Cmax)n(t½)p (with m≈ 0.7, n ≈ –1, and p ≈  –½) reduced it further, to 
~1/32. In contrast, using (weight)d(Cmax)f(age)g gave no improvement over (weight)d(Cmax)f. The authors conclude 
that the inconsistency in AUC can be reduced 10-fold with dosing proportional to the weight and the drug 
pharmacokinetic parameters [(weight0.7) (Cmax t½ 0.5)].  
 
 
Variability in the integrated quantity of free plasma cisplatin, typically measured as area under a curve of plasma 
concentration versus time (AUC), is a significant clinical problem.1-6 Peng et al, for example, stated, “BSA-based 
dosing of cisplatin in children is not satisfactory.” 4(p1823) Similarly, a pediatric formula for carboplatin dosing that 
involves glomerular filtration rate is currently receiving attention.7-11 However, a solution to the inconstancy 
problem for cisplatin (an approach that assures desired AUC for all patients) is lacking. Reducing this inconstancy 
assures effective treatment for all patients and minimizes the toxicity.  
 We evaluate here the variability of free (unbound) plasma cisplatin pharmacokinetics in 19 patients who 
participated in the phase I trial 9970 within the Children Oncology Group.6 Cisplatin was administered 
intravenously in combination with irinotecan. The cisplatin dose was proportional to body surface area (BSA), 30 
mg/m2. Values of AUC were calculated from plasmameasurements taken after drug administration. The variability, 
calculated as the ratio of population SD in AUC to mean AUC, was ~1/3, unacceptably high. We investigated the 
effect of other dosing formulas based on patient parameters. Using the results of this investigation, we developed a 
formula for cisplatin dosing that resulted in much more constant AUC (smaller variability). 
 
Materials and Methods 
 
Materials 
Platinum (Pt) atomic spectroscopy standard (H2PtCl6, 1 mg/mL in 10% hydrochloride) was purchased from 
PerkinElmer (Norwalk, Conn), nitric acid Ultrex II ultrapure reagent was purchased from J. T. Baker (Phillipsburg, 
NJ), and Amicon Centrifree micropartition unit (30 000 Mr cutoff, catalog #4104) was purchased from Millipore 
(Billerica, Mass).[End of page 443] 
 
Patients 
Nineteen patients (7 female patients and 12 male patients) received 1-hour intravenous infusion of cisplatin at 30 
mg/m2. All patients had normal serum creatinine and glomerular filtration rate for age and normal serum albumin 
≥2.5 g/dL. Body surface area was determined as [square root of height (cm) × weight (kg)] ÷ 60. Blood samples (1 
mL each) for plasma cisplatin determinations were drawn from central lines into EDTA tubes before cisplatin 
infusion and then at 0, 15, 30, 45, 60, and 90 minutes from the end of cisplatin infusion. The samples were 
centrifuged immediately at 4°C, and an aliquot of the plasma was centrifuged in the Amicon Centrifree 
micropartition unit in a fixed-angle rotor (4°C, 2000g) for 1 hour. The ultrafiltrates were stored at –20°C, shipped on 
dry ice, and analyzed for cisplatin content immediately on arrival using atomic absorption spectroscopy.6 A more 
complete description of the study design, treatment, and assay validation has been reported previously.6  
 The participating sites were phase I institutions within the Children Oncology Group. The study was 
approved by the institutional review board of the participating institutions. Written informed consent was obtained 
for each patient before they entered the study. 
 
Platinum Analysis 
Platinum analysis was done on the graphite furnace of a Shimadzu atomic absorption spectrometer. The instrument 
was supplied with a hollow cathode Pt lamp, deuterium arc background correction, and graphite tubes. Argon gas 
and tap water flowed through the furnace. The Pt standard (H2PtCl6) was a 51.3 nM (0.01 mg/L) solution, freshly 
prepared by serial dilutions of the Pt atomic spectroscopy standard stock in dH2O plus1% HNO3 (volume to 
volume). A calibration curve was generated immediately before each measurement. It was linear from 0 to 1.0 pmol 
(r ≥ .99); the lower limit of detection was ~0.1 pmol. Each sample was measured in triplicate. The injection volume 
was 20 μL. The furnace program was drying at 70°C for 10 seconds, drying at 90°C for 10 seconds, drying at 120°C 
for 10 seconds, charring at 250°C for 10 seconds, charring at 800°C for 25 seconds, charring at 30°C for 20 seconds, 
atomizing at 2600°C for 5 seconds, and burn off at 3000°C for 3 seconds. Calculations were based on the molecular 
weight of Pt of 195.078. 
 
Data Analysis 
The AUC was calculated for each patient from the values of the maximum concentration (Cmax, plasma 
concentration at the end of cisplatin infusion, μM) and k (decay constant obtained by fitting measured plasma 
concentrations to Ae–kt, minute–1). Details of the calculation are given below. The relative standard deviation (RSD) 
was determined as population SD of AUC divided by mean AUC. The smallness of RSD is a measure of constancy. 
 To estimate AUC for dosing schemes other than BSA, the AUC for each patient was assumed proportional 
to the administered dose, that is,AUC for dose D1 is calculated as AUC for dose D2 multiplied by D1/D2. This 
assumption is exact for linear kinetics for all values ofD10,13; it approaches exactness in general when D1 is close to 
D2 because it represents the leading term in a power-series expansion of AUC as a function of D. The assumption of 
proportionality enabled us to estimate AUC for any dosing scheme from the AUC measured for BSA-based dosing. 
We then investigated combinations of patients’ parameters that would make AUC as constant as possible (give 
smallest RSD).  
 The AUC was calculated as a sum of 2 parts, C(1) and C(2). The contribution for time (t) greater than 60 
minutes, C(2),was calculated from Cmax and half-life (t½), assuming free plasma of the molar concentration of 
cisplatin ([cisplatin]) decayed exponentially with a decay constant k = ln(2)/t½: 
 
 
 
 The exponential decay was verified from the measured plasma concentrations. The contribution for t < 60 
minutes, C(1), cannot be calculated exactly because no measurements of free plasma [cisplatin] were made during 
drug infusion. Lower and upper bounds on C(1) can be obtained assuming free plasma [cisplatin] rises linearly with t 
until it reaches the steady-state value Cmax. The lower bound on C(1) with this assumption, corresponding to free 
plasma [cisplatin] = Cmax × (t ÷ 60) is C(1)=Cmax × 30 minutes. The upper bound, assuming a fast rise in C, so free 
plasma [cisplatin] ≈ Cmax for t ≤ 60 minutes, is C(1)=Cmax × 60 minutes. The actual value of C(1) for slow infusion 
should be between these 2 values. 12 The high and low AUC values were calculated by adding Cmax t½/ln 2 to either 
Cmax × 60 or Cmax × 30, and [End of page 444] 
 
 
 
calculations were made with both assumptions. Conclusions drawn from the 2 sets of AUC values were very similar. 
 
Results 
In each patient, the drug decay was monoexponential. Table I shows the measured values of Cmax and t½ for the 19 
patients for BSA-based dosing and calculated high and low values of AUC. For all patients, Cmax for free plasma 
cisplatin was [mean ± SD (n)] 4.7 ± 1.6 (19) μM and t½ was 25.4 ± 5.4 (19) minutes. The RSD in AUC (high or low) 
for all patients was 0.320. 
  We then searched for an optimal usage of patients’ weight (Wt) and height (Ht) to determine dosing. 
Dosing was set proportional to (weight)a(height)b and the predicted AUC was calculated as (AUC from BSA based 
dosing) ÷ [(weight)½(height)½] × [(weight)a (height)b]. The optimal values of the exponents a and b were determined 
by minimizing RSD for the predicted AUCs. The results of these calculations are shown in Table II (optimal Ht/Wt 
dosing). For the high AUC, the optimal values of a and b were 0.61 and 0.19, respectively (giving RSD = 0.319). 
For the low AUC, the optimal values of a and b were 0.60 and 0.31, respectively (giving RSD = 0.319). 
  The RSD of 0.319 is essentially the same as that obtained using BSA, that is, a = b = 0.5 (Table I). This 
finding is not surprising because height and weight are correlated, and thus only the sum of the exponents is of 
importance. To show this, we calculated the AUC for dosing proportional to (weight)c(height)1–c. The RSD is[End 
of page 445] 
 
 
 
plotted versus c in Figure 1. Varying c between 0.1 and 0.9 increased RSD by less than 10% from BSA dosing (c = 
0.5).Therefore, not much was gained by dosing proportional to the geometric mean of height and weight (BSA) 
rather than by either height, weight, or (weight)c (height)1–c with 0 < c < 1. 
  The above results suggested patients’ parameters other than height and weight must be taken into account 
to improve constancy in AUC. These parameters might include rates of drug elimination, distribution, and 
biotransformation, which were reflected in the measured Cmax and t½. Because the RSD in Cmax was greater than that 
in t½ and because the RSD in weight was greater than that in height (Table I), we considered dosing proportional to 
(weight)d × (Cmax)f. The predicted values of AUC were calculated by dividing the values of AUC in Table I by 
(BSA/ BSA) and multiplying them by (weight/ weight)d and by  where brackets indicate mean values. 
The mean values were incorporated in the formula so that predicted AUC would be the same size as those of Table 
I. We then sought the values of d and f, which gave the smallest calculated RSD in AUC. 
  The results (Table II) demonstrated a great improvement in constancy over BSA-based dosing. The best 
values of d and f were 0.78 and –1.01 for the low AUC results and 0.75 and –1.01 for the high AUC results. (The 
inverse proportionality to Cmax is not surprising, given that calculated AUC is proportional to Cmax, but simply 
dosing inversely to Cmax cannot achieve constancy in AUC.) The RSD was reduced to 0.113 and 0.083, respectively. 
Thus, dosing proportional to (weight)3/4/Cmax reduced the RSD to ~1/10, 3 times lower than the value obtained with 
BSA dosing. 
  One can lower the RSD even further by dosing proportional to powers of 3 patients’ parameters, that is, 
(Wt)m(Cmax)n(t½)p. We calculated the resultant AUC according to the following: [End of page 446] 
 
 
 
and optimized by minimizing RSD with respect to m, n, and p. For low AUC, the optimum values of the exponents 
were m= 0.69, n = –1.03, p = –0.61; the RSD was only 0.031. For high AUC, the optimum values of the exponents 
were almost the same: m= 0.69, n = –1.03, p = –0.44; the RSD was again 0.031. Thus, a lowering in RSD by another 
factor of 3 was achieved.  
 To investigate whether this substantial lowering was simply a consequence of using 3 rather than 2 
parameters, we considered dosing proportional to (weight)m(age)n(Cmax)p. For low AUC, the results were m = 0.78, n 
= –0.003, p = –1.00 (RSD = 0.113). For high AUC, the results were m = 0.75, n = 0.002, p = –1.01 (RSD = 0.083). 
Because the exponent of age was essentially zero (so the other exponents had the values they did in the 2-parameter 
dosing formula), taking patients’ age into account presented no advantage. 
 
Discussion 
It is clear that BSA dosing is associated with significant variability in AUC (RSD ~ 1/3) (Table I). In our 
calculations, we use a few parameters (height, weight, age, Cmax, and t½) to construct a cisplatin dosing formula that 
gives more constant AUC. Insignificant lowering of RSD in AUC, relative to BSA dosing, was obtained using 
patients’ height and weight only. The reason for the variability in AUC resulting from BSA dosing thus appears to 
be related to variables other than height and weight, such as rates of drug elimination, distribution, and 
biotransformation.12-14 None of these parameters is currently evaluated in patients receiving cisplatin. However, Cmax 
(plasma drug concentration at the end of infusion) is measured and reflects these parameters. 
  Our calculations show RSD in AUC can be reduced from ~1/3 (for BSA dosing) to ~1/10 if dosing is 
proportional to (weight)3/4/Cmax. They suggest that a further reduction by a factor of 3 in RSD can be achieved by 
dosing proportional to powers of 3 parameters: weight, Cmax, and t½. On the other hand, dosing proportional to 
powers of weight, Cmax, and age gives no improvement over dosing proportional only to powers of the first 2 
variables. This finding confirms the source of the variation in AUC is kinetics, and parameters such as Cmax and t½ 
should be taken into account to produce constancy. The former is more easily obtained because it requires only a 
single measurement, whereas t½ requires a series of measurements. 
  As an example of use of the 3-parameter dosing formula, suppose our target value of AUC is 367.5, which 
is the mean value of the low and high AUCs for all patients, ½(435 + 300) (Table I). To establish the constant of 
proportionality in the dosing formula,we divide the AUC for each patient (Table I) by [30 mg/m2 × BSA (in m2)] 
and multiply by [(Wt0.7)(Cmax –1)(t½ –½)], giving new AUCs with a mean value of 5.619. Because our target 
value is 367.5, we multiply all doses by 367.5/5.619 = 65.4. Our calculations predict that if the administered 
cisplatin doses were (65.4) × [(Wt0.7)(Cmax –1)(t½ –½)], the mean AUC would be 367.5, and the population SD would 
be 11.99, making the RSD 0.0326. Based on the formula, patient 1 (Table I) would receive a cisplatin dose of 
65.4(44.3)0.7 ÷ (5.8 × 27½) = 30.8 mg instead of 40.6 mg = (30 mg/m2)(1.354 m2). In contrast, patient 2 would 
receive a cisplatin dose of 65.4(51.0)0.7 ÷ (3.2 × 25½) = 64.1 mg instead of 45.7 mg = (30 mg/m2)(1.524 m2). All our 
calculations are based on the approximation that changing a patient’s dose from D1 to D2 will change the patient’s 
AUC from A1 to (D2/D1)A1; this approximation approaches exactness when D2/D1 approaches unity. 
  Our aim in this work was to find a dosing formula, based on easily measurable patients’ parameters, which 
would reduce the variability in delivered AUC from the present high level (RSD ~1/3 using BSA, dosing 
proportional to (Ht × Wt)½). Using powers of height and weight only, one can get only minimal improve- [End of 
page 477] ment, but RSD can be reduced by a factor of 3with dosing proportional to (Wt)3/4/Cmax. Another factor of 3 
improvement in RSD is possible for dosing proportional to [(Wt0.7)(Cmax –1)(t½ –½)], but the measurement of t½ is more 
complicated than the measurement of Cmax. The proposed method for cisplatin dosing requires clinical validation by 
future studies. Nevertheless, the data show that pharmacokinetics variables (Cmax and t½) contribute importantly to 
cisplatin AUC variations. Thus, limited pharmacokinetics samples may be necessary, especially during high-dose 
cisplatin treatment or when treating young infants. For example, when high-dose cisplatin is given (ie, 20-40 
mg/m2/day ⋅ 5 consecutive days), limited pharmacokinetics samples could be collected on day 1 to guide the dosing 
on days 2 through 5. 
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